Study identifier:D0102C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
[14C] AZD8931 - A Phase I, Open Label Study of the Absorption, Metabolism, Excretion, and Pharmacokinetics Following a Single Oral Dose to Healthy Male Subjects
Healthy
Phase 1
Yes
[14C] AZD8931
Male
6
Interventional
50 Years - 65 Years
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Study to Assess the Absorption, Metabolism and Excretion of [14C]AZD8931 after a Single-Dose Oral Administration
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: AZD8931 [14C] AZD8931 | Drug: [14C] AZD8931 Single 160 mg oral dose administered on Day 1 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.